Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,262,596
  • Shares Outstanding, K 70,615
  • Annual Sales, $ 270,260 K
  • Annual Income, $ 14,080 K
  • 60-Month Beta 0.27
  • Price/Sales 4.60
  • Price/Cash Flow N/A
  • Price/Book 2.83
Trade KNSA with:

Options Overview Details

View History
  • Implied Volatility 61.17% ( -0.44%)
  • Historical Volatility 25.61%
  • IV Percentile 57%
  • IV Rank 50.63%
  • IV High 101.26% on 07/21/23
  • IV Low 20.06% on 10/16/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 29
  • Volume Avg (30-Day) 193
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 4,312
  • Open Int (30-Day) 4,913

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.56 +7.97%
on 04/19/24
20.16 -11.32%
on 03/27/24
-2.09 (-10.47%)
since 03/26/24
3-Month
16.56 +7.97%
on 04/19/24
22.09 -19.06%
on 03/04/24
-0.34 (-1.87%)
since 01/26/24
52-Week
10.65 +67.97%
on 05/01/23
22.09 -19.06%
on 03/04/24
+6.73 (+60.36%)
since 04/26/23

Most Recent Stories

More News
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,099.96 (+1.02%)
NVO : 126.85 (+0.84%)
BIIB : 208.90 (+3.18%)
KNSA : 17.88 (+1.53%)
SWTX : 45.53 (+3.01%)
RLAY : 6.37 (+3.49%)
ADPT : 2.60 (-0.38%)
GS : 427.57 (+1.79%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 38.57 (+0.29%)
KNSA : 17.88 (+1.53%)
ACAD : 16.71 (+2.45%)
HRMY : 29.32 (+1.35%)
AMPH : 41.11 (+0.69%)
INCY : 51.68 (+0.98%)
AGEN : 11.69 (+40.84%)
NVS : 97.44 (-1.64%)
PFE : 25.40 (+0.55%)
SGEN : 228.74 (-0.07%)
MRK : 131.20 (+0.37%)
RXDX : 199.92 (+0.09%)
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday

The company reported a big jump in revenue and updated guidance.

KNSA : 17.88 (+1.53%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

KNSA : 17.88 (+1.53%)
TRVN : 0.3910 (-4.40%)
After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

KNSA : 17.88 (+1.53%)
Centene (CNC) Expands Evolent Partnership to Boost Quality

Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.

AMPH : 41.11 (+0.69%)
CNC : 74.00 (-2.22%)
EVH : 27.65 (-2.37%)
KNSA : 17.88 (+1.53%)
HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza

HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.

AMPH : 41.11 (+0.69%)
HCA : 306.69 (-2.37%)
KNSA : 17.88 (+1.53%)
PNTG : 20.78 (+2.31%)
Select Medical (SEM) Forays Into Indiana With Lutheran Health JV

Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.

AMPH : 41.11 (+0.69%)
SEM : 27.41 (+0.07%)
KNSA : 17.88 (+1.53%)
PNTG : 20.78 (+2.31%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

KNSA : 17.88 (+1.53%)
ABSI : 4.58 (+2.81%)
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 9.09% and 8.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

APLS : 49.86 (+4.03%)
KNSA : 17.88 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 18.74
2nd Resistance Point 18.40
1st Resistance Point 18.14
Last Price 17.88
1st Support Level 17.54
2nd Support Level 17.19
3rd Support Level 16.93

See More

52-Week High 22.09
Last Price 17.88
Fibonacci 61.8% 17.72
Fibonacci 50% 16.37
Fibonacci 38.2% 15.02
52-Week Low 10.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar